{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:05:27Z","timestamp":1780452327761,"version":"3.54.1"},"reference-count":23,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1509,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1111\/j.1600-0609.2011.01637.x","type":"journal-article","created":{"date-parts":[[2011,4,28]],"date-time":"2011-04-28T14:56:36Z","timestamp":1304002596000},"page":"157-168","source":"Crossref","is-referenced-by-count":31,"title":["Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000 - a report from the population-based CAMELIA Registry"],"prefix":"10.1111","volume":"87","author":[{"given":"Edgar","family":"Faber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Mu\u017e\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladim\u00edr","family":"Koza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Deme\u010dkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslava","family":"Voglov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0139udmila","family":"Demitrovi\u010dov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juraj","family":"Chudej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imrich","family":"Markuljak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Cmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Koz\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"T\u00f3thov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jaro\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladislav","family":"Du\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Indr\u00e1k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,15]]},"reference":[{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-\u03b1-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with combination interferon-\u03b1 plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.bbmt.2006.03.012","article-title":"Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era","volume":"12","author":"Grigg","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/bmt.2008.218","article-title":"Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase","volume":"42","author":"Bittencourt","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/leu.2008.225","article-title":"A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials","volume":"22","author":"Lucas","year":"2008","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/sj.leu.2404509","article-title":"Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe - impact of cost considerations","volume":"21","author":"Gratwohl","year":"2007","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"871A","DOI":"10.1182\/blood.V110.11.2964.2964","article-title":"Incidence, comorbidity and treatment survey of chronic myeloid leukemia in Germany","volume":"110","author":"Hasford","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"764.e1","DOI":"10.1016\/j.amjmed.2010.03.018","article-title":"Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia","volume":"123","author":"Wiggins","year":"2010","journal-title":"Am J Med"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal-time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe against cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/leu.2008.245","article-title":"Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph\/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany","volume":"23","author":"Rohrbacher","year":"2009","journal-title":"Leukemia"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB19|cit19","unstructured":"Institute of Health Information and Statistics of the Czech Republic Cancer Incidence 2007 in the Czech Republic 2010 1 262"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.leukres.2010.07.001","article-title":"\u201cReal-life\u201d results of front-line treatment with imatinib in older patients (\u226565\u2003years) with newly diagnosed chronic myelogenous leukemia","volume":"34","author":"Latagliata","year":"2010","journal-title":"Leuk Res"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.0902-4441.2005.t01-1-EJH2321.x","article-title":"Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicenter study","volume":"76","author":"Bornh\u00e4user","year":"2006","journal-title":"Eur J Haematol"},{"key":"10.1111\/j.1600-0609.2011.01637.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2011.01637.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-0609.2011.01637.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T06:04:05Z","timestamp":1625637845000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2011.01637.x"}},"subtitle":["CAMELIA Registry report on CML treatment"],"short-title":[],"issued":{"date-parts":[[2011,7,15]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2011.01637.x","relation":{},"ISSN":["0902-4441"],"issn-type":[{"value":"0902-4441","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,15]]}}}